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PreviewsLife, Death, and Ubiquitin:
Taming the Mule
Ubiquitin-mediated protein degradation is an efficient
way for the cell to get rid of unwanted proteins. A key
player in this process is the E3 ubiquitin ligase. In this
issue of Cell, Chen et al. (2005) and Zhong et al. (2005)
describe a new E3 ligase, ARF-BP1/Mule, which tar-
gets two very different substrates, p53 and Mcl-1, with
completely different cellular outcomes.
Last year, Hershko, Ciechanover, and Rose were awarded
the Nobel Prize in Chemistry for the discovery of ubiq-
uitin-mediated protein degradation. In this tightly regu-
lated process, proteins are tagged with ubiquitin moie-
ties through a series of enzymatic reactions involving
an E1-activating enzyme, an E2-conjugating enzyme,
and an E3 ubiquitin ligase. Tagged proteins are then
degraded by the 26S proteasome (Hershko and Ciecha-
nover, 1998). The E3 ligases are the “brain” of this pro-
cess and determine substrate specificity. Hence, they
are attractive candidates for therapeutic targets. In the
current issue of Cell, Chen et al. (2005) and Zhong et
al. (2005) describe a new E3 ligase, ARF-BP1/Mule, a
gigantic (nearly 500 kDa) protein that possesses some
unexpected structural features and mediates complex
biological effects.
The two groups identified ARF-BP1/Mule by taking
very different approaches. Chen and colleagues (Chen
et al., 2005) set out to identify new regulators of the p53
tumor suppressor network. Following oncogenic and
genotoxic stress signals, p53 is stabilized and bio-
chemically activated, leading to transcriptional upregu-
lation or repression of a multitude of target genes
(Oren, 2003). Transcriptional alterations mediated by
p53 result in a variety of cell fate changes, including
growth arrest and apoptosis. This serves to prevent
damaged cells from giving rise to progeny with de-
fective genomes that eventually may spawn formation
of tumors. Normally, the cell maintains low levels of p53
through rapid ubiquitin-dependent proteolysis of this
tumor suppressor protein. Several E3 ligases have been
implicated in this process, including the major negative
regulator of p53, Mdm2 (Oren, 2003), as well as the
more recently described COP1 and PIRH2 (Dornan et
al., 2004; Leng et al., 2003). Another important regulator
of p53 stability is the tumor suppressor protein ARF
(Lowe and Sherr, 2003). Oncogenic stress induces ex-
pression of ARF, which then binds to Mdm2 in the cell
nucleus or nucleolus and blocks the E3 activity of
Mdm2, promoting p53 stabilization (see Figure 1). How-
ever, ARF can also operate in an Mdm2- and p53-inde-
pendent manner (Lowe and Sherr, 2003). Thus, overex-
pression of ARF inhibits the proliferation of cells that
lack both p53 and Mdm2, and deletion of ARF results
in a wider range of tumor types and accelerated tumor
formation in double null mice lacking both p53 andMdm2. Hence, ARF probably targets other proteins in
addition to Mdm2.
In their search for ARF binding proteins that are likely
to underlie the p53-independent effects of ARF, Chen
et al. (2005) came up with a new protein that interacts
with ARF, which they dubbed ARF-BP1 (binding protein
1). From its sequence, the authors deduced that this
protein is a novel E3 ligase. Indeed, ARF-BP1 was
shown to possess E3 activity, which was inhibited by
ARF. Fulfilling their initial suspicions, they were able to
mimic faithfully the effects of ARF overexpression in
p53 null cells using RNAi-mediated ablation of ARF-
BP1, resulting in growth inhibition. Hence, the p53-
independent antiproliferative effects of ARF can be at-
tributed at least in part to the ability of ARF to neutralize
ARF-BP1. Surprisingly, when p53 was present, ARF-
BP1 ablation also resulted in stabilization and activa-
tion of p53. Further analysis revealed that ARF-BP1
binds directly to p53 and ubiquitylates this tumor sup-
pressor, firmly establishing ARF-BP1 as an additional
E3 ligase that targets p53. Remarkably, the biological
outcome of ARF-BP1 ablation in p53-positive cells was
enhancement of p53-mediated apoptosis.
Apoptosis is a highly regulated active program of cell
death that is crucial for normal development and tissue
homeostasis. Compromised apoptosis, or conversely
excessive apoptosis, results in many human diseases,
including cancer and neurodegenerative diseases. Pro-
teins of the Bcl-2 family are lead players in apoptosis
and are roughly divided into proapoptotic and anti-
apoptotic members. In response to various stress sig-
nals, proapoptotic members of the Bcl-2 family enable
the release from mitochondria of apoptogenic factors
such as cytochrome c and Smac/DIABLO. This leads to
activation of caspases, which are proteases that cleave
specific proteins and induce the morphological and
biochemical features of apoptosis.
One prosurvival member of the Bcl-2 family, Mcl-1, is
important for development and for responses to envi-
ronmental cues (Michels et al., 2005). Unlike most other
members of the family, Mcl-1 is a short-lived protein,
the expression and antiapoptotic activity of which is
normally controlled by the ubiquitin/proteasome path-
way.Using aclassical biochemical fractionation approach,
Zhong et al. (2005) set out to identify the E3 ligase re-
sponsible for Mcl-1 ubiquitylation and degradation. The
quest yielded a new E3 ligase, which they called Mule
(short for Mcl-1 ubiquitin ligase E3). In addition to con-
taining a HECT domain required for its E3 activity, Mule
also harbors a BH3 (Bcl-2 homology 3) domain. BH3
domains mediate protein-protein interactions within the
Bcl-2 family; indeed, the BH3 domain of Mule is neces-
sary for its specific association with its substrate, Mcl-1.
Downregulation of Mule expression resulted in stabili-
zation and accumulation of Mcl-1; in line with the
known antiapoptotic effects of Mcl-1, this rendered the
cells more resistant to killing by genotoxic agents. Un-
expectedly, Mule turns out to be identical to ARF-BP1.
ARF-BP1/Mule thus regulates the stability of two very
different proteins, p53 and Mcl-1.
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964Figure 1. Proposed Mode of Action of ARF-
BP1/Mule
When the cell is under basal nonstress con-
ditions or when the p53 response is termi-
nated, p53 is efficiently ubiquitylated by both
Mdm2 and ARF-BP1/Mule, resulting in its
rapid degradation. Oncogene activation
leads to upregulation of ARF expression and
results in binding of ARF to both Mdm2 and
ARF-BP1/Mule. This results in blocking the
nuclear activity of ARF-BP1/Mule, an E3 li-
gase. Inactivation of this E3 ligase causes
the accumulation of p53, leading to apopto-
sis or growth inhibition. On the other hand,
ARF-BP1/Mule in the cytoplasm ubiqui-
tylates Mcl-1 and promotes its degradation.
In this case, ARF-BP1/Mule activity, rather
than inactivity, facilitates apoptosis. The in-
teraction of ARF-BP1/Mule with Mcl-1 may
occur in the cytoplasm as well as in mito-
chondria. p53 can translocate to mitochondria
in some apoptotic scenarios. This transloca-
tion, as well as the fate of mitochondrial p53,
may also be subject to regulation by ARF-
BP1/Mule. TCTP, whose expression is re-
pressed by p53, can prevent Mcl-1 ubiquitylation, perhaps by counteracting the activity of ARF-BP1/Mule. “Active” and “inactive” relate to
the activity state of the E3 ligases ARF-BP1/Mule and Mdm2.Comparison of the findings reported by Zhong et al. s
b(2005) and Chen et al. (2005) reveals that the biological
implications of the two studies appear to differ widely. o
sWhereas Chen et al. assign to ARF-BP1/Mule an antia-
poptotic function (via p53 degradation), Zhong et al. con- c
Tclude that it actually promotes apoptosis (via Mcl-1
degradation). This is most vividly illustrated by the t
pseemingly contradictory outcomes of ARF-BP1/Mule
RNAi-mediated knockdown: reduced survival of p53- 2
bpositive cells in one study (Chen et al., 2005) versus
increased survival in the other study (Zhong et al., M
w2005). The fact that both groups used exactly the same
cell line (U2OS) makes this picture even more enig- d
tmatic. One must assume that the biological impact of
ARF-BP1/Mule is regulated in subtle ways, leading to t
mvery different outcomes even under superficially similar
conditions. Relative availability of growth/survival fac- M
ptors, differences in cell-cell interactions, and different
types of stress inadvertently inflicted on the cells may p
tprovide at least a partial explanation for this apparent
inconsistency. e
How does one incorporate the divergent effects of
ARF-BP1/Mule into a coherent picture? One possibility t
uis that, under normal conditions, ARF-BP1/Mule helps
to maintain homeostatic levels of p53 and Mcl-1, com- f
Fpatible with survival and proliferation. Aberrant onco-
gene activation leads to ARF induction and inhibition M
(of ARF-BP1/Mule activity toward p53 in the nucleus,
thereby facilitating apoptosis (see Figure 1). In the cyto- a
Hplasm, where ARF is not abundant, oncogene activa-
tion and possibly other types of stress may instead lead m
eto ARF-BP1/Mule being targeted to Mcl-1, causing
rapid Mcl-1 degradation and further promoting apopto- t
lsis. Whether and how the subcellular localization of
ARF-BP1/Mule is indeed controlled in a signal-depen- i
odent manner remains to be explored.
p53 is a highly connected protein positioned in the t
scenter of an intricate network of feedback loops andignaling cascades (Oren, 2003). It therefore would not
e surprising if p53 is found capable of modulating the
utcome of ARF-BP1/Mule action, rather than merely
erving as its obedient ubiquitylation target. In fact, re-
ent work suggests that this may well be the case.
hus, the cancer-associated protein TCTP (transla-
ionally controlled tumor protein) binds to Mcl-1 and
revents its ubiquitylation and degradation (Liu et al.,
005). Although the underlying mechanism remains to
e elucidated, it is not unlikely that TCTP may shield
cl-1 from ARF-BP1/Mule or even interact physically
ith this E3 ligase to prevent it from promoting Mcl-1
egradation. Interestingly, TCTP expression is nega-
ively regulated by p53 (Cans et al., 2003). It is tempting
o speculate that, during a vigorous p53 response, p53-
ediated downregulation of TCTP enables ARF-BP1/
ule to preferentially target Mcl-1 while letting go of
53. This is predicted to set the stage for efficient apo-
tosis. Notably, it is unlikely that ARF and TCTP are
he only regulators of ARF-BP1/Mule activity, and the
lucidation of additional regulators cannot be far off.
What is the point of having a single E3 ligase that
argets both a positive (p53) and a negative (Mcl-1) reg-
lator of apoptosis? First, it should be noted that this
unctional categorization is not as tight as it appears.
or instance, there also exists a shorter form of Mcl-1,
cl-1S, that is generated by alternative splicing
Michels et al., 2005). Mcl-1S retains the BH3 domain
nd thus should be able to bind to ARF-BP1/Mule.
owever, unlike full-length Mcl-1, Mcl-1S actually pro-
otes apoptosis. Hence, downregulation of Mcl-1S is
xpected to increase survival. Conversely, p53 some-
imes can actually exert antiapoptotic effects, particu-
arly in the absence of acute stress. This may occur, for
nstance, via p53-mediated maintenance of basal levels
f p21 (Oren, 2003). Nevertheless, it does remain true
hat p53 and Mcl-1 often have opposing effects on cell
urvival. It is plausible that, under most physiological
Previews
965conditions, ARF-BP1/Mule does not downregulate p53
and Mcl-1 simultaneously. The biological and molecular
principles that guide the selective choice of targets by
ARF-BP1 may therefore hold the key to the enigma.
Owing to its ability to control the levels of key mole-
cules such as p53 and Mcl-1, ARF-BP1/Mule is likely
to be important in cell fate determination. Its large size
suggests that, in addition to the HECT E3 domain and
the structural motifs mediating binding of p53 and
Mcl-1, ARF-BP1/Mule may hide numerous additional
molecular secrets. Future work should unravel those
secrets and enable the proper positioning of ARF-BP1/
Mule within the highly dynamic network of signals that
underpins cell fate decisions.
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